This exploratory Phase IIA trial found that participants with type 2 diabetes and hypertension treated for 2 weeks with the sGC stimulator praliciguat had trends toward improvement in metabolic and haemodynamic outcomes. This evidence concerns the gene SGCB and hypertensive disorder.